Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension

NCT ID: NCT06747884

Last Updated: 2025-07-30

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-06-06
• Study Completion Date: 2030-06-30

Brief Summary

This is a natural history study to improve the types of assessments and biological samples that will be used in clinical drug trials in both congenital myotonic dystrophy and childhood myotonic dystrophy.

Detailed Description

Congenital Myotonic Dystrophy (CDM) is a multi-systemic, dominantly inherited disorder caused by a trinucleotide repeat expansion (CTGn) in the DMPK gene. Children with CDM present at birth with respiratory insufficiency, talipes equiovarus, feeding difficulties and hypotonia. There is a 30% mortality rate in the first year of life. As children grow, they are at risk for intellectual impairment, autistic features, gastrointestinal symptoms, and motor delay. Childhood onset myotonic dystrophy (ChDM) is similarly multisystem and is classified as onset after birth but before 10 years of age. It likely represents a less severe form of CDM.

Currently, there is an ongoing therapeutic trial in adults with DM1 using an antisense oligonucleotide to target the destruction of the CTG repeat. The ability to conduct this trial in children is directly limited by the lack of available data regarding appropriate clinical endpoints and biomarkers. Although the underlying mechanism is the same in adult DM1 and CDM, there are specific challenges to directly transferring outcome measures into the CDM population. First, our cross-sectional data demonstrates age-related improvement in several functional outcome measures, such as the 6-minute walk. Second, in the adult DM1 clinical trial, RNA splicing changes in the tibialis anterior muscle are a primary endpoint because they correlate with functional measures. However, our pilot data with described splicing changes does not clearly correlate with the adult clinical phenotype.

This study is designed to establish valid and reliable clinical outcome assessments for children with congenital and childhood myotonic dystrophy, and to develop biomarkers for the condition.

This study will enroll up to 200 children with CDM and ChDM at participating sites. No treatment will be administered as part of this study. Patients will receive standard of care as determined by their treating physician. Study visits will occur at Baseline, Month 12, and Month 24.

Conditions

Congenital Myotonic Dystrophy; Childhood Myotonic Dystrophy; Myotonic Dystrophy

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Congenital myotonic dystrophy (CDM)

Children with congenital myotonic dystrophy. No intervention will be administered to either group.

No interventions assigned to this group

Childhood Myotonic Dystrophy

Children with childhood myotonic dystrophy. No intervention will be administered to either group.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Age 5-17 years, 11 months at enrollment. Lower age limit not applicable for participants who have completed ASPIRE-DM1 protocol. Upper age limit not applicable for participants who previously participated in TREAT-01-001 (TREAT-CDM) study
• A diagnosis of CDM, defined as: children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
• Written, voluntary informed consent must be obtained before any study related procedures are conducted.

• Age 3-17 years, 11 months at enrollment. Upper age limit not applicable for participants who previously participated in TREAT-01-001 (TREAT-CDM) study.
• A diagnosis of ChDM, defined as: children having cognitive deficits, muscle weakness, myotonia that developed after age 1 and prior to age 10 and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
• Written, voluntary informed consent must be obtained before any study related procedures are conducted.

Exclusion Criteria

• Any other non-DM1 illness that would interfere with the ability to undergo safe testing or would affect the interpretation of the results, in the opinion of the site investigator
• Significant trauma within the past month
• Internal metal or devices (exclusion for DEXA component)
• Use of anticoagulants, such as warfarin or a direct oral anticoagulant (e.g., dabigatran) due to the increased risk of bleeding with biopsy
• Platelet count <50,000
• History of a bleeding disorder
• Participation in a clinical trial involving an investigational product
• History of adverse reaction to lidocaine (if participating in muscle biopsy)

• Minimum Eligible Age: 3 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

Sponsor Role: collaborator

SUNY Research Foundation

OTHER

Sponsor Role: collaborator

University of Minnesota

OTHER

Sponsor Role: collaborator

Roseman University of Health Sciences

OTHER

Sponsor Role: collaborator

University of California, San Diego

OTHER

Sponsor Role: collaborator

University of Glasgow

OTHER

Sponsor Role: collaborator

University of Kansas Medical Center

OTHER

Sponsor Role: collaborator

Virginia Commonwealth University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nicholas Johnson, MD, MSCI, FAAN

Role: PRINCIPAL_INVESTIGATOR

Virginia Commonwealth University

Locations

Virginia Commonwealth University

Richmond, Virginia, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Ruby Langeslay, MPH

Role: CONTACT

Ruby.Langeslay@vcuhealth.org

804-828-6318

Facility Contacts

Shantel Kyles

Role: primary

shantel.brown@vcuhealth.org

804-828-3381

Levi Headrick

Role: backup

levi.headrick@vcuhealth.org

References

Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord. 2000 Jun;30(3):237-43. doi: 10.1023/a:1005596502855.

Reference Type: BACKGROUND

PMID: 11055459 (View on PubMed)

Ehlers S, Gillberg C, Wing L. A screening questionnaire for Asperger syndrome and other high-functioning autism spectrum disorders in school age children. J Autism Dev Disord. 1999 Apr;29(2):129-41. doi: 10.1023/a:1023040610384.

Reference Type: BACKGROUND

PMID: 10382133 (View on PubMed)

Huckabee ML, McIntosh T, Fuller L, Curry M, Thomas P, Walshe M, McCague E, Battel I, Nogueira D, Frank U, van den Engel-Hoek L, Sella-Weiss O. The Test of Masticating and Swallowing Solids (TOMASS): reliability, validity and international normative data. Int J Lang Commun Disord. 2018 Jan;53(1):144-156. doi: 10.1111/1460-6984.12332. Epub 2017 Jul 5.

Reference Type: BACKGROUND

PMID: 28677236 (View on PubMed)

Porter K, Smart S, Hennessey N, Cocks N. Chewing skills in two and three year old children: Gender and age comparisons on an adapted version of the test of mastication and swallowing (TOMASS-C). Int J Speech Lang Pathol. 2024 Feb;26(1):38-44. doi: 10.1080/17549507.2022.2152867. Epub 2022 Dec 13.

Reference Type: BACKGROUND

PMID: 36511843 (View on PubMed)

Frank U, van den Engel-Hoek L, Nogueira D, Schindler A, Adams S, Curry M, Huckabee ML. International standardisation of the test of masticating and swallowing solids in children. J Oral Rehabil. 2019 Feb;46(2):161-169. doi: 10.1111/joor.12728. Epub 2018 Oct 27.

Reference Type: BACKGROUND

PMID: 30307651 (View on PubMed)

Patel R, Connaghan K, Franco D, Edsall E, Forgit D, Olsen L, Ramage L, Tyler E, Russell S. "The caterpillar": a novel reading passage for assessment of motor speech disorders. Am J Speech Lang Pathol. 2013 Feb;22(1):1-9. doi: 10.1044/1058-0360(2012/11-0134). Epub 2012 Jul 30.

Reference Type: BACKGROUND

PMID: 22846881 (View on PubMed)

Berggren KN, Hung M, Dixon MM, Bounsanga J, Crockett B, Foye MD, Gu Y, Campbell C, Butterfield RJ, Johnson NE. Orofacial strength, dysarthria, and dysphagia in congenital myotonic dystrophy. Muscle Nerve. 2018 Sep;58(3):413-417. doi: 10.1002/mus.26176.

Reference Type: BACKGROUND

PMID: 29901230 (View on PubMed)

Gavazzi F, Adang L, Waldman A, Jan AK, Liu G, Lorch SA, DeMauro SB, Shults J, Pierce SR, Ballance E, Kornafel T, Harrington A, Glanzman AM, Vanderver A. Reliability of the Telemedicine Application of the Gross Motor Function Measure-88 in Patients With Leukodystrophy. Pediatr Neurol. 2021 Dec;125:34-39. doi: 10.1016/j.pediatrneurol.2021.09.012. Epub 2021 Sep 24.

Reference Type: BACKGROUND

PMID: 34624609 (View on PubMed)

McDonald CM, Marden JR, Shieh PB, Wong BL, Lane H, Zhang A, Nguyen H, Frean M, Trifillis P, Koladicz K, Signorovitch J. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status. J Comp Eff Res. 2023 Apr;12(4):e220190. doi: 10.57264/cer-2022-0190. Epub 2023 Feb 7.

Reference Type: BACKGROUND

PMID: 36749302 (View on PubMed)

Eriksson BM, Ekstrom AB, Peny-Dahlstrand M. Daily activity performance in congenital and childhood forms of myotonic dystrophy type 1: a population-based study. Dev Med Child Neurol. 2020 Jun;62(6):723-728. doi: 10.1111/dmcn.14395. Epub 2019 Nov 8.

Reference Type: BACKGROUND

PMID: 31701525 (View on PubMed)

Johnson NE, Ekstrom AB, Campbell C, Hung M, Adams HR, Chen W, Luebbe E, Hilbert J, Moxley RT 3rd, Heatwole CR. Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy. Dev Med Child Neurol. 2016 Jul;58(7):698-705. doi: 10.1111/dmcn.12948. Epub 2015 Oct 28.

Reference Type: BACKGROUND

PMID: 26510705 (View on PubMed)

Johnson NE, Butterfield R, Berggren K, Hung M, Chen W, DiBella D, Dixon M, Hayes H, Pucillo E, Bounsanga J, Heatwole C, Campbell C. Disease burden and functional outcomes in congenital myotonic dystrophy: A cross-sectional study. Neurology. 2016 Jul 12;87(2):160-7. doi: 10.1212/WNL.0000000000002845. Epub 2016 Jun 15.

Reference Type: BACKGROUND

PMID: 27306634 (View on PubMed)

Timchenko L. Correction of RNA-Binding Protein CUGBP1 and GSK3beta Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1. Int J Mol Sci. 2019 Dec 21;21(1):94. doi: 10.3390/ijms21010094.

Reference Type: BACKGROUND

PMID: 31877772 (View on PubMed)

Charlet-B N, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell. 2002 Jul;10(1):45-53. doi: 10.1016/s1097-2765(02)00572-5.

Reference Type: BACKGROUND

PMID: 12150906 (View on PubMed)

Wagner SD, Struck AJ, Gupta R, Farnsworth DR, Mahady AE, Eichinger K, Thornton CA, Wang ET, Berglund JA. Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy. PLoS Genet. 2016 Sep 28;12(9):e1006316. doi: 10.1371/journal.pgen.1006316. eCollection 2016 Sep.

Reference Type: BACKGROUND

PMID: 27681373 (View on PubMed)

Osborne RJ, Lin X, Welle S, Sobczak K, O'Rourke JR, Swanson MS, Thornton CA. Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet. 2009 Apr 15;18(8):1471-81. doi: 10.1093/hmg/ddp058. Epub 2009 Feb 17.

Reference Type: BACKGROUND

PMID: 19223393 (View on PubMed)

Wheeler TM. Myotonic dystrophy: therapeutic strategies for the future. Neurotherapeutics. 2008 Oct;5(4):592-600. doi: 10.1016/j.nurt.2008.08.001.

Reference Type: BACKGROUND

PMID: 19019311 (View on PubMed)

Mankodi A, Teng-Umnuay P, Krym M, Henderson D, Swanson M, Thornton CA. Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol. 2003 Dec;54(6):760-8. doi: 10.1002/ana.10763.

Reference Type: BACKGROUND

PMID: 14681885 (View on PubMed)

Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, Cannon SC, Thornton CA. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell. 2002 Jul;10(1):35-44. doi: 10.1016/s1097-2765(02)00563-4.

Reference Type: BACKGROUND

PMID: 12150905 (View on PubMed)

Campbell C, Sherlock R, Jacob P, Blayney M. Congenital myotonic dystrophy: assisted ventilation duration and outcome. Pediatrics. 2004 Apr;113(4):811-6. doi: 10.1542/peds.113.4.811.

Reference Type: BACKGROUND

PMID: 15060232 (View on PubMed)

Johnson NE, Luebbe E, Eastwood E, Chin N, Moxley RT 3rd, Heatwole CR. The impact of congenital and childhood myotonic dystrophy on quality of life: a qualitative study of associated symptoms. J Child Neurol. 2014 Jul;29(7):983-6. doi: 10.1177/0883073813484804. Epub 2013 Apr 22.

Reference Type: BACKGROUND

PMID: 23611887 (View on PubMed)

Campbell C, Levin S, Siu VM, Venance S, Jacob P. Congenital myotonic dystrophy: Canadian population-based surveillance study. J Pediatr. 2013 Jul;163(1):120-5.e1-3. doi: 10.1016/j.jpeds.2012.12.070. Epub 2013 Feb 14.

Reference Type: BACKGROUND

PMID: 23415617 (View on PubMed)

Johnson NE, Butterfield RJ, Mayne K, Newcomb T, Imburgia C, Dunn D, Duval B, Feldkamp ML, Weiss RB. Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program. Neurology. 2021 Feb 16;96(7):e1045-e1053. doi: 10.1212/WNL.0000000000011425. Epub 2021 Jan 20.

Reference Type: BACKGROUND

PMID: 33472919 (View on PubMed)

Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, Neville C, Narang M, Barcelo J, O'Hoy K, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science. 1992 Mar 6;255(5049):1253-5. doi: 10.1126/science.1546325.

Reference Type: BACKGROUND

PMID: 1546325 (View on PubMed)

Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, Hunter K, Stanton VP, Thirion JP, Hudson T, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992 Feb 21;68(4):799-808. doi: 10.1016/0092-8674(92)90154-5.

Reference Type: BACKGROUND

PMID: 1310900 (View on PubMed)

Fu YH, Pizzuti A, Fenwick RG Jr, King J, Rajnarayan S, Dunne PW, Dubel J, Nasser GA, Ashizawa T, de Jong P, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science. 1992 Mar 6;255(5049):1256-8. doi: 10.1126/science.1546326.

Reference Type: BACKGROUND

PMID: 1546326 (View on PubMed)

Other Identifiers

R01NS104010-07A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

TREAT-01-002

Identifier Type: -

Identifier Source: org_study_id